The company plans to combine the CAR designs with its in-house delivery platform to advance its in vivo CAR-M therapies toward clinical studies.

The firm received FDA feedback on the design of registrational studies of VS-7375, while it awaits new data for Avmapki Fakzynja.

Day One received accelerated approval in the US in 2024 for Ojemda to treat pediatric low-grade glioma with a BRAF fusion or rearrangement or BRAF V600 mutation.

Allarity Therapeutics said on Friday it has closed a $20 million non-convertible debt financing transaction with venture capital firm Streeterville Capital. The financing is structured as a note ...

The deal could be worth more than $1 billion, if all genetic targets identified lead to approved therapeutics.

Investigators at CHOP and UPenn found that lower cell counts could still be associated with poor outcomes if the cells were ...